Study design: epidemiological point prevalence study~Target population: Patients with haloperidol treatment~The following aspects will be investigated:~The medication profiles will be checked for drug interactions with risk of QT-prolongation.~Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.~Safety measurements (e.g. ECG) will be documented.
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.